Search Results for 'fda'

Search For:
Refine by Dates:
From: To:
Refine By Content:

  • FDA Approves Pfizer's Eraxis

    February 22, 2006
    Pfizer has received approval from the FDA for Eraxis to treat candidemia, a potentially life-threatening bloodstream infection. Candidemia is the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximate…

  • FDA Approves Pfizer's Eraxis

    February 22, 2006
    Pfizer has received approval from the FDA for Eraxis to treat candidemia, a potentially life-threatening bloodstream infection. Candidemia is the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximate…

  • Sanofi-Aventis Gets FDA Response for Rimonabant

    February 21, 2006
    Sanofi-Aventis has received an approvable letter from the FDA's Division of Metabolism and Endocrinology Products for rimonabant for weight management, and a non-approvable letter from the Division of Anesthesia, Analgesia and Rheumathology Products,…

  • Sanofi-Aventis Gets FDA Response for Rimonabant

    February 21, 2006
    Sanofi-Aventis has received an approvable letter from the FDA's Division of Metabolism and Endocrinology Products for rimonabant for weight management, and a non-approvable letter from the Division of Anesthesia, Analgesia and Rheumathology Products,…

  • FDA Grants Gardasil Priority Review

    February 7, 2006
    Merck & Co.'s BLA for Gardasil, the investigational cervical cancer vaccine, has been accepted and granted priority review by the FDA. A priority designation is intended for products that address unmet medical needs. Under the Prescription Drug U…

  • FDA Grants Gardasil Priority Review

    February 7, 2006
    Merck & Co.'s BLA for Gardasil, the investigational cervical cancer vaccine, has been accepted and granted priority review by the FDA. A priority designation is intended for products that address unmet medical needs. Under the Prescription Drug U…

  • FDA Grants Plavix Priority Review

    January 18, 2006
    Sanofi-Aventis and Bristol-Myers Squibb's sNDA for Plavix for treatment of patients with acute ST-segment elevation myocardial infarction (STEMI) has been accepted for review by the FDA. STEMI is a heart attack in which an artery is generally blocked…

  • FDA Grants Plavix Priority Review

    January 18, 2006
    Sanofi-Aventis and Bristol-Myers Squibb's sNDA for Plavix for treatment of patients with acute ST-segment elevation myocardial infarction (STEMI) has been accepted for review by the FDA. STEMI is a heart attack in which an artery is generally blocked…